Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?
Thromb Res
.
2021 Dec:208:170-172.
doi: 10.1016/j.thromres.2021.11.008.
Epub 2021 Nov 16.
Authors
Marco Zuin
1
,
Carlo Cervellati
2
,
Gianluca Rigatelli
3
,
Giovanni Zuliani
2
,
Loris Roncon
3
Affiliations
1
Department of Translational Medicine, University of Ferrara, Ferrara, Italy. Electronic address: marco.zuin@edu.unife.it.
2
Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
3
Department of Cardiology, Rovigo General Hospital, Rovigo, Italy.
PMID:
34801920
PMCID:
PMC8594077
DOI:
10.1016/j.thromres.2021.11.008
No abstract available
Keywords:
COVID-19; IL-6 antagonists; Venous thromboembolism.
Publication types
Letter
Comment
MeSH terms
COVID-19*
Humans
Interleukin-6
SARS-CoV-2
Venous Thromboembolism* / drug therapy
Venous Thrombosis*
Substances
Interleukin-6